Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity‐induced insulin resistance

• Main Authors: Melissa L. Borg (Author), Julie Massart (Author), Thais De Castro Barbosa (Author), Adrià Archilla‐Ortega (Author), Jonathon A.B. Smith (Author), Johanna T. Lanner (Author), Jorge Alsina‐Fernandez (Author), Benjamin Yaden (Author), Alexander E. Culver (Author), Håkan K.R. Karlsson (Author), Joseph T. Brozinick (Author), Juleen R. Zierath (Author)
• Format: Book
• Published: Wiley, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Type 2 diabetes and obesity are often seen concurrently with skeletal muscle wasting, leading to further derangements in function and metabolism. Muscle wasting remains an unmet need for metabolic disease, and new approaches are warranted. The neuropeptide urocortin 2 (UCN2) and...